Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#91 / 200 Total
ACDC - ProFrac Holding Corp - Stock Price Chart
CompanyProFrac Holding Corp
IndustryOil & Gas Equipment & Services
Market Cap1.82BEPS (ttm)1.45
P/E7.84EPS this Y-59.18%
Forward P/E6.92EPS next Y95.91%
PEG-EPS past 5Y-
P/S0.60EPS next 5Y-4.00%
P/B1.42EPS Q/Q-
Dividend-Sales Q/Q20.24%
Insider Own87.77%Inst Own11.73%
Insider Trans2.54%Inst Trans1.74%
Short Float15.92%EarningsAug 10/b
Analyst Recom1.57Target Price28.07
Avg Volume577.01K52W Range9.01 - 27.00
ProFrac Holding Corp. operates as a holding company with interest in manufacturing and distribution of fracturing units & pumps and provides related services. The company was founded on August 17, 2021 and is headquartered in Willow Park, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THRC Holdings, LP10% OwnerJun 14Buy13.40186,1482,494,38371,636,571Jun 15 05:50 PM
THRC Holdings, LP10% OwnerJun 13Buy13.4198,9111,326,39771,450,423Jun 15 05:50 PM
THRC Holdings, LP10% OwnerJun 09Buy12.6364,783818,20971,351,512Jun 12 05:52 PM
THRC Holdings, LP10% OwnerJun 08Buy12.33437,1565,390,13371,286,729Jun 12 05:52 PM
Klein Heather NChief Administrative OfficerJun 02Sale12.0025,444305,32866,199Jun 05 04:05 PM
TDW - Tidewater Inc. - Stock Price Chart
CompanyTidewater Inc.
IndustryOil & Gas Equipment & Services
Market Cap3.84BEPS (ttm)0.96
P/E76.37EPS this Y1433.64%
Forward P/E9.74EPS next Y121.99%
PEG15.27EPS past 5Y-
P/S4.89EPS next 5Y5.00%
P/B4.16EPS Q/Q-
Dividend-Sales Q/Q31.52%
Insider Own7.85%Inst Own82.28%
Insider Trans3.17%Inst Trans19.84%
Short Float7.09%EarningsAug 07/a
Analyst Recom1.40Target Price71.20
Avg Volume879.20K52W Range20.34 - 73.16
Tidewater, Inc. engages in the provision of offshore marine support and transportation services to the offshore energy industry. The firm offers the towing of, and anchor handling for, mobile offshore drilling units, transporting supplies and personnel necessary to sustain drilling, work over and production activities, offshore construction and seismic and subsea support, geotechnical survey for wind farm construction, and a variety of specialized services such as pipe and cable laying. It operates through the following geographical segments: Americas, Asia Pacific, Middle East, Europe and Mediterranean, and West Africa. The company was founded in 1955 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBOTTI ROBERTDirectorSep 07Buy67.321,486100,0333,235,657Sep 11 10:47 AM
Darling David EEVP, COOSep 06Sale67.4519,2501,298,412103,780Sep 07 09:11 PM
Darling David EEVP, COOSep 05Sale68.4125017,102123,030Sep 07 09:11 PM
Rubio Samuel REVP, CFO & CAOAug 14Sale62.3721,7881,358,918117,677Aug 16 08:56 PM
ROBOTTI ROBERTDirectorAug 10Buy63.0048,2003,036,4463,234,171Aug 11 04:39 PM
IRTC - iRhythm Technologies Inc - Stock Price Chart
CompanyiRhythm Technologies Inc
IndustryMedical Devices
Market Cap2.79BEPS (ttm)-3.28
P/E-EPS this Y24.24%
Forward P/E-EPS next Y29.69%
PEG-EPS past 5Y-24.46%
P/S6.17EPS next 5Y-
P/B12.45EPS Q/Q24.34%
Dividend-Sales Q/Q21.64%
Insider Own1.49%Inst Own109.65%
Insider Trans-1.40%Inst Trans0.44%
Short Float7.76%EarningsAug 03/a
Analyst Recom1.42Target Price141.80
Avg Volume340.94K52W Range82.51 - 140.23
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bobzien BriceChief Financial OfficerAug 09Sale111.291,356150,90918,608Aug 10 04:20 PM
Day Mark J.Chief Technology OfficerAug 03Option Exercise36.2248617,60355,522Aug 04 08:48 AM
Shrishrimal SumiEVP, Chief Risk OfficerJun 02Sale111.451,109123,59818,707Jun 05 04:07 PM
Wilson Daniel G.EVP, Corp Dev Inv RelMar 29Sale125.004,000500,00035,337Mar 30 07:32 PM
Day Mark J.Chief Technology OfficerMar 03Sale117.232,116248,05954,815Mar 07 02:06 PM
CREG - Smart Powerr Corp - Stock Price Chart
CompanySmart Powerr Corp
IndustryUtilities - Renewable
Market Cap9.62MEPS (ttm)-0.56
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y41.45%
P/S-EPS next 5Y-
P/B0.09EPS Q/Q-2.91%
Dividend-Sales Q/Q-
Insider Own31.77%Inst Own2.10%
Insider Trans0.00%Inst Trans30.03%
Short Float0.03%Earnings-
Analyst Recom-Target Price-
Avg Volume21.47K52W Range1.00 - 3.38
Smart Powerr Corp. engages in the provision of energy savings and recycling products and services. It offers waste energy recycling projects for industrial applications and develops a Build-Operate-Transfer model to provide energy saving and recovery facilities for multiple energy intensive industries in China. The company was founded by Guo Hua Ku on May 8, 1980 and is headquartered in Xi'an, China.
BPTS - Biophytis ADR - Stock Price Chart
CompanyBiophytis ADR
Market Cap7.04MEPS (ttm)-14.70
P/E-EPS this Y78.64%
Forward P/E-EPS next Y-33.33%
PEG-EPS past 5Y36.53%
P/S-EPS next 5Y-
Dividend-Sales Q/Q-
Insider Own50.48%Inst Own0.00%
Insider Trans0.00%Inst Trans-71.97%
Short Float2.78%Earnings-
Analyst Recom2.00Target Price71.78
Avg Volume1.51M52W Range0.88 - 9.02
Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and Rene Lafont on September 27, 2006 and is headquartered in Paris, France.
FHTX - Foghorn Therapeutics Inc - Stock Price Chart
CompanyFoghorn Therapeutics Inc
Market Cap250.74MEPS (ttm)-2.74
P/E-EPS this Y-4.02%
Forward P/E-EPS next Y18.20%
PEG-EPS past 5Y-38.31%
P/S11.54EPS next 5Y-
P/B-EPS Q/Q-7.16%
Dividend-Sales Q/Q24.70%
Insider Own58.88%Inst Own30.72%
Insider Trans-1.25%Inst Trans-0.32%
Short Float9.70%EarningsAug 04/b
Analyst Recom1.29Target Price18.17
Avg Volume65.22K52W Range4.51 - 9.97
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Agresta SamuelChief Medical OfficerAug 16Option Exercise3.72311,2971,158,025311,297Aug 18 04:03 PM
Agresta SamuelChief Medical OfficerAug 16Sale8.25311,2972,568,2000Aug 18 04:03 PM
IMMX - Immix Biopharma Inc - Stock Price Chart
CompanyImmix Biopharma Inc
Market Cap57.07MEPS (ttm)-0.81
P/E-EPS this Y-36.81%
Forward P/E-EPS next Y-6.36%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.32EPS Q/Q-111.19%
Dividend-Sales Q/Q-
Insider Own74.19%Inst Own3.91%
Insider Trans1.22%Inst Trans36.31%
Short Float1.71%Earnings-
Analyst Recom1.00Target Price11.00
Avg Volume141.57K52W Range0.68 - 3.65
Sep-22-23 12:04PM Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-21-23 08:55AM U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis (GlobeNewswire) +15.38%
Sep-19-23 09:10AM Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +24.15%
Sep-15-23 01:18PM Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX) ( +5.12%
Sep-07-23 10:38AM The 3 Best Speculative Stocks to Buy Now: September 2023 (InvestorPlace)
08:41AM Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference (GlobeNewswire)
Sep-01-23 08:39AM Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board (GlobeNewswire) +12.81%
Aug-23-23 08:37AM U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma (GlobeNewswire) +11.11%
Aug-18-23 09:20AM Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board (GlobeNewswire) +6.13%
Aug-16-23 09:05AM Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) (GlobeNewswire)
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hsu JasonDirectorSep 15Buy2.497,00017,396757,000Sep 18 07:03 PM
Hsu JasonDirectorSep 14Buy2.5810,00025,772750,000Sep 18 07:03 PM
Ng CareyDirectorSep 14Buy2.5810,00025,76010,000Sep 15 06:27 PM
Hsu JasonDirectorSep 12Buy2.8330,00084,864740,000Sep 18 07:03 PM
Adams Helen C.DirectorSep 12Buy2.9613,00038,49213,000Sep 14 05:20 PM
APLT - Applied Therapeutics Inc - Stock Price Chart
CompanyApplied Therapeutics Inc
Market Cap166.64MEPS (ttm)-1.25
P/E-EPS this Y46.62%
Forward P/E-EPS next Y20.93%
PEG-EPS past 5Y-55.15%
P/S15.63EPS next 5Y-
P/B-EPS Q/Q61.07%
Dividend-Sales Q/Q-
Insider Own31.35%Inst Own56.88%
Insider Trans0.00%Inst Trans-9.92%
Short Float5.28%EarningsAug 10/b
Analyst Recom1.33Target Price7.67
Avg Volume647.93K52W Range0.50 - 2.90
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARCUS JOEL SDirectorSep 15Option Exercise1.0512,37512,994453,414Sep 19 08:08 PM
Shendelman ShoshanaPresident and CEOJan 11Sale0.9115,87014,442751,625Jan 13 04:34 PM
Perfetti RiccardoChief Medical OfficerJan 11Sale0.916,0535,508154,856Jan 13 04:32 PM
Hansard AdamChief Commercial OfficerJan 11Sale0.914,4954,09092,475Jan 13 04:30 PM
Shendelman ShoshanaPresident and CEOOct 14Buy0.6550,00032,250767,495Oct 14 05:41 PM
BLRX - Bioline Rx Ltd ADR - Stock Price Chart
CompanyBioline Rx Ltd ADR
Market Cap127.39MEPS (ttm)-0.73
P/E-EPS this Y-103.23%
Forward P/E-EPS next Y-
PEG-EPS past 5Y34.62%
P/S-EPS next 5Y-
P/B6.05EPS Q/Q-93.21%
Dividend-Sales Q/Q-
Insider Own0.56%Inst Own2.01%
Insider Trans0.00%Inst Trans257.16%
Short Float7.30%EarningsAug 30/b
Analyst Recom1.00Target Price12.50
Avg Volume1.10M52W Range0.55 - 2.53
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
QTRX - Quanterix Corp - Stock Price Chart
CompanyQuanterix Corp
IndustryMedical Devices
Market Cap1.03BEPS (ttm)-1.77
P/E-EPS this Y60.26%
Forward P/E-EPS next Y-17.24%
PEG-EPS past 5Y20.63%
P/S9.19EPS next 5Y-
P/B2.90EPS Q/Q76.02%
Dividend-Sales Q/Q32.04%
Insider Own9.37%Inst Own87.18%
Insider Trans0.58%Inst Trans-7.47%
Short Float3.01%EarningsAug 07/a
Analyst Recom2.00Target Price28.25
Avg Volume353.75K52W Range8.02 - 28.77
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DONNELLY WILLIAM PDirectorSep 08Buy24.8520,200501,97828,438Sep 11 04:07 PM
MEISTER PAUL MDirectorJun 07Option Exercise2.8923,33567,438287,970Jun 08 04:25 PM